Posted by Michael Wonder on 11 Jul 2023
MHRA authorises GSK’s Arexvy, the first respiratory syncytial virus vaccine for older adults
10 July 2023 - The authorisation is based on phase III efficacy data in older adults.
GSK today announced that the MHRA has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older.
